Theragen Etex Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
213
- Stock Symbol
-
066700
- Investments
-
3
- Share Price
-
$2.14
- (As of Thursday Closing)
Theragen Etex General Information
Description
Theragen Etex Co Ltd is a Korea-based company mainly engaged in the manufacturing and selling of finished pharmaceutical products and providing genome sequencing services. It also provides healthcare services. The company's operating segments include its Pharmaceutical business and the Healthcare and Genome Analysis Business. A majority of its revenue is generated from the Pharmaceutical Business which involves the manufacturing and sales of specialized and general medicine along with new drug research and development. The Healthcare and Genome Analysis Business involves DNA sequence analysis, RNA mutation genome analysis and decoding, and the distribution of non-prescription drugs for healthcare purposes. Geographically, the company derives its key revenue from the domestic market.
Contact Information
Website
www.theragenetex.comCorporate Office
- Daegwan Building
- 190 Gangnam-daero, Seocho-gu
- Seoul
- South Korea
Corporate Office
- Daegwan Building
- 190 Gangnam-daero, Seocho-gu
- Seoul
- South Korea
Theragen Etex Stock Performance
As of 15-May-2025, Theragen Etex’s stock price is $2.14. Its current market cap is $78.6M with 36.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.14 | $2.12 | $1.78 - $3.04 | $78.6M | 36.7M | 94.3K | -$0.94 |
Theragen Etex Financials Summary
As of 31-Dec-2024, Theragen Etex has a trailing 12-month revenue of $183M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 98,134 | 98,134 | 125,761 | 131,071 |
| Revenue | 182,951 | 182,951 | 165,567 | 147,641 |
| EBITDA | (25,763) | (25,763) | 30,759 | 15,445 |
| Net Income | (30,038) | (30,038) | 20,048 | 7,400 |
| Total Assets | 160,901 | 160,901 | 188,670 | 195,226 |
| Total Debt | 34,268 | 34,268 | 28,166 | 24,722 |
Theragen Etex Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Theragen Etex Comparisons
Industry
Financing
Details
Theragen Etex Competitors (6)
One of Theragen Etex’s 6 competitors is Personalis, a Formerly VC-backed company based in Fremont, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Personalis | Formerly VC-backed | Fremont, CA | ||||
| Twist Bioscience | Formerly VC-backed | South San Francisco, CA | ||||
| Parexel International | Private Equity-Backed | Durham, NC | ||||
| 10x Genomics | Formerly VC-backed | Pleasanton, CA | ||||
| WuXi AppTec | Formerly PE-Backed | Shanghai, China |
Theragen Etex Patents
Theragen Etex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | Active | 17-Sep-2018 | ||
| US-20220033359-A1 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | Active | 17-Sep-2018 | ||
| EP-3854787-A1 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | Inactive | 17-Sep-2018 | ||
| EP-3854787-A4 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | Inactive | 17-Sep-2018 | ||
| ES-2393125-T3 | A method to stimulate angiogenesis using dkk2 and composition comprising the same | Active | 24-May-2006 | C07K14/47 |
Theragen Etex Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Theragen Etex Investments (3)
Theragen Etex’s most recent deal was a Later Stage VC with Graphene Square for . The deal was made on 24-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Graphene Square | 24-Apr-2025 | Later Stage VC | Other Metals, Minerals and Mining | ||
| Celloram | 01-Jan-2020 | Seed Round | Drug Discovery | ||
| Celleron Therapeutics | 31-Jan-2017 | Later Stage VC | Drug Discovery |
Theragen Etex ESG
Risk Overview
Risk Rating
Updated June, 13, 2021
48.95 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Pharmaceuticals
Industry
of 947
Rank
Percentile
Pharmaceuticals
Subindustry
of 452
Rank
Percentile
Theragen Etex Exits (1)
Theragen Etex’s most recent exit was on 31-Jan-2017 from Celleron Therapeutics. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Celleron Therapeutics | 31-Jan-2017 | Completed |
|
Theragen Etex FAQs
-
When was Theragen Etex founded?
Theragen Etex was founded in 1990.
-
Where is Theragen Etex headquartered?
Theragen Etex is headquartered in Seoul, South Korea.
-
What is the size of Theragen Etex?
Theragen Etex has 213 total employees.
-
What industry is Theragen Etex in?
Theragen Etex’s primary industry is Biotechnology.
-
Is Theragen Etex a private or public company?
Theragen Etex is a Public company.
-
What is Theragen Etex’s stock symbol?
The ticker symbol for Theragen Etex is 066700.
-
What is the current stock price of Theragen Etex?
As of 15-May-2025 the stock price of Theragen Etex is $2.14.
-
What is the current market cap of Theragen Etex?
The current market capitalization of Theragen Etex is $78.6M.
-
What is Theragen Etex’s current revenue?
The trailing twelve month revenue for Theragen Etex is $183M.
-
Who are Theragen Etex’s competitors?
Personalis, Twist Bioscience, Parexel International, 10x Genomics, and WuXi AppTec are some of the 6 competitors of Theragen Etex.
-
What is Theragen Etex’s annual earnings per share (EPS)?
Theragen Etex’s EPS for 12 months was -$0.94.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
